Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Nxstage Medical, Inc. (NXTM) Discloses Form 4 Insider Selling : Exec. Joseph E ... - OTC Outlook |
 |
 |
|
Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 2,000 shares on Jun 23, 2015. The Insider selling transaction was disclosed on Jun 24, 2015 to the Securities and Exchange Commission. The shares were sold at $15.36 per share for a total value of $30,720.00 according to InsiderTradingReport. Shares of NxStage Medical, Inc. (NASDAQ:NXTM) ended Thursday session in red amid volatile trading. The shares closed down 0.02 points or 0.13% at $14.96 with 398,871 shares getting traded. Post opening the session at $15.07, the shares hit an intraday low of $14.88 and an intraday high of $15.1 and the price vacillated in this range throughout the day. The company has a market cap of $946 million and the number of outstanding shares has been calculated to be 63,238,000 shares. The 52-week high of NxStage Medical, Inc. (NASDAQ:NXTM) is $19.63 and the 52-week low is $11.5. Based on the current information, company Insiders own 2.3% of Nxstage Medical, Inc. shares. In the past six months, there is a change of -5.3% in the total insider ownership. Institutional Investors own 96% of Company shares. During last 3 month period, 2.45% of total institutional ownership has changed in the company shares. The Company has disclosed insider buying and selling activities to the Securities Exchange,The (Chief Executive Officer) of Nxstage Medical, Inc., Burbank Jeffrey H sold 20,000 shares at $$15.56 on June 17, 2015. The Insider selling transaction had a total value worth of $311,200. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. The shares are up 5.81% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $16.22 and the 200 day moving average is recorded at $17.46. S&P 500 has rallied 8.4% during the last 52-weeks. Company has received price target recommendation from many analysts. In the latest statement by the brokerage house, Canaccord Genuity maintains its outlook on NxStage Medical, Inc. (NASDAQ:NXTM). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $24 per share to $27 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
